摘要
第一部分尿液可溶性T细胞免疫球蛋白粘蛋白分子-3(sTim-3)对移植肾急性排异无创性诊断及预测的价值
目的：通过回顾性检测研究尿液可溶性T细胞免疫球蛋白粘蛋白分子-3(sTim-3)在肾移植患者发生急性排异时的变化,探讨sTim-3在移植肾急性排异中的诊断价值,同时进行前瞻性动态检测肾移植术后早期移植患者尿液中sTim-3的变化,进一步评估sTim-3在移植受者免疫状态监测中的作用。
方法：选择2006.1-2009.10在本中心接受肾脏移植患者(有病理活检并且保留有完整尿液标本)中,术后1年内血肌酐较基础值升高25-30%以上且移植肾活检病理诊断为急性排异49例,移植肾功能稳定且术后1-2月程序活检病理诊断为移植肾状态(未见组织学损害,No-AR)58例,移植肾功能稳定且术后1-2月程序活检病理诊断为亚临床排异10例,病理证实的急性肾小管坏死9例以及慢性移植肾肾病29例。同时留取健康对照者晨尿尿标本40份。用ELISA的方法测定上述尿液sTim-3的水平(检测结果均用尿肌酐值校正),比较术后不同时间、不同组别之间sTim-3水平的差异,并用免疫组化的方法研究急性排异者、移植肾状态者Tim-3表达的差异。
结果：49例急性排异患者尿液sTim-3的水平(4257±439.4,95%CI：3373-5142ng/mmol creatine)明显高于肾功能稳定患者(1433±107.2,95%CI：1218-1648ng/mmol creatine)和健康对照组患者(1269±99.3,95%CI：1068-1469ng/mmol creatine),构建诊断急性排异的ROC曲线,曲线下面积0.874(95%CI：0.8-0.948,P<0.001),结合特异性和敏感性最适组合,当sTim-3=1836ng/mmol creatinine,诊断急性排异的敏感性和特异性分别达到89.4%和82.5%,P<0.001。急性排异患者sTim-3的水平与急性肾小管坏死患者(2180±217,95%CI：1679-2680ng/mmol creatine)相比也有统计学差异(P=0.02)。在术后早期的动态观察中我们发现,急性排异组sTim-3术后一周内平均水平都在6000ng/mmol creatinine左右,而肾功能稳定组患者的sTim-3水平在术后逐渐下降,到了术后第五天左右就达到稳定状态约2000 ng/mmol creatinine左右。同时我们也发现急性排异患者肾组织中Tim-3表达增多,正常肾移植患者基本没有发现Tim-3蛋白的表达。
结论：作为无创性检查的手段,首次发现尿液sTim-3在诊断急性排异,鉴别是否为耐激素排异和亚临床排异方面有较好的敏感度和特异度,该蛋白分子可能是监测移植肾免疫状态的新方法。
第二部分尿液Fractalkine对移植肾急性排异无创性诊断及预测的价值
目的：通过回顾性检测研究尿液Fractalkine在肾移植患者发生急性排异时的变化,探讨Fractalkine在移植肾急性排异中的诊断价值,同时进行前瞻性动态检测肾移植术后早期移植患者尿液中Fractalkine的变化,进一步评估Fractalkine在移植受者免疫状态监测中的作用。
方法：选择2006.1-2009.10在本中心接受肾脏移植患者(有病理活检并且保留有完整尿液标本)中,术后1年内血肌酐较基础值升高25-30%以上且移植肾活检病理诊断为急性排异49例,移植肾功能稳定且术后1-2月程序活检病理诊断为移植肾状态(未见组织学损害,No-AR)58例,移植肾功能稳定且术后1-2月程序活检病理诊断为亚临床排异10例,病理证实的急性肾小管坏死9例以及慢性移植肾肾病29例。同时留取健康对照者晨尿尿标本40份。用ELISA的方法测定上述尿液Fractalkine的水平(检测结果均用尿肌酐值校正),比较术后不同时间、不同组别之间Fractalkine水平的差异,并用免疫组化的方法研究急性排异者、移植肾状态者Fractalkine表达的差异。
结果：49例急性排异患者尿液Fractalkine的水平(429.1±56.1,95%CI:316.2-541.9ng/mmol creatine)明显高于肾功能稳定患者(94.6±8.4,95%CI:77.9-111.3ng/mmol creatine)和健康对照组患者(84.5±8.9,95%CI：66.5-102.6ng/mmol creatine),构建诊断急性排异的ROC曲线,曲线下面积0.909(95%CI：0.856-0.962,P<0.001),结合特异性和敏感性最适组合,当Fractalkine= 144.6 ng/mmol creatinine,诊断急性排异的敏感性和特异性分别达到84%和81%,P<0.001。急性排异患者Fractalkine的水平与急性肾小管坏死患者(133±9.8,95%CI：110.3-155.7ng/mmol creatine)(P<0.0001)。在术后早期的动态观察中我们发现,急性排异组Fractalkine术后三周内平均水平都维持在较高水平约400-600ng/mmol creatinine左右,明显高于肾功能稳定组患者的Fractalkine水平(100-150ng/mmol creatinine左右)。同时我们也发现急性排异患者肾组织中Fractalkine表达增多,可见多个小管的胞膜、管腔膜以及管周血管内皮细胞染成棕黄色,正常肾移植患者偶见Fractalkine表达。
结论：作为无创性检查的手段,发现尿液Fractalkine在诊断急性排异中有较好的敏感度和特异度,并且能较早预测移植肾急性排异的发生。同时发生急性排异时,Fractalkine在肾小管上皮细胞和管周血管内皮细胞上的表达明显增强。
第三部分尿液B细胞趋化因子-1(BCA-1)对移植肾急性排异诊断及排异类型鉴别的价值
目的：通过回顾性检测研究尿液BCA-1在肾移植患者发生急性排异时的变化,探讨BCA-1在移植肾急性排异及排异类型中的诊断价值,同时进行前瞻性动态检测肾移植术后早期移植患者尿液中BCA-1的变化,进一步评估BCA-1在移植受者免疫状态监测中的作用。
方法：选择2006.1-2009.10在本中心接受肾脏移植患者(有病理穿刺并且保留有完整尿液标本)中,术后1年内血肌酐较基础值升高25-30%以上且移植肾活检病理诊断为急性排异49例,移植肾功能稳定且术后1-2月程序活检病理诊断为移植肾状态(未见组织学损害,No-AR)58例,以及慢性移植肾肾病29例。同时留取健康对照者晨尿尿标本40份。用ELISA的方法测定上述尿液BCA-1的水平(尿标本的数据均用尿肌酐值校正),比较术后不同时间、不同组别之间BCA-1水平的差异。
结果：49例急性排异患者尿液BCA-1的水平(8.1±2.1,95%CI：3.9-12.4pg/μmol creatine)明显高于肾功能稳定患者(0.65±0.3,95%CI：0.044-1.26pg/μmol creatine)和慢性移植肾肾病组患者(2.2±0.8,95%CI；0.69-3.78pg/μmol creatine),健康对照组患者几乎都低于检测低限。构建诊断急性排异的ROC曲线,曲线下面积0.881(95%CI：0.811-0.951),结合特异性和敏感性最适组合,当BCA-1=0.23pg/μmol creatinine,诊断急性排异的敏感性和特异性分别达到81.6%和87.9%。我们还发现急性体液性排异患者的BCA-1的水平(24.2±6.7pg/μmol creatinine)显著高于急性细胞性排异患者的水平(2.9±0.6pg/μmol creatinine),P=0.009。构建诊断急性体液性排异的ROC曲线,曲线下面积0.867(95%CI：0.725-1.005),结合特异性和敏感性最适组合,当BCA-1=8.3pg/μmol creatinine,诊断急性体液性排异的敏感性和特异性分别达到75%和91.9%。在术后早期的动态观察中我们发现,急性排异组BCA-1术后3周内平均水平都维持在2 pg/μmol creatinine以上,而肾功能稳定组患者的BCA-1水平都维持在2 pg/μmol creatinine以下。
结论：应用无创性检测尿液BCA-1水平的方法,首次为临床提供了一个非常有用的辅助诊断指标,通过观察BCA-1水平的变化,我们能较好地诊断移植肾急性排异以及急性排异的类型。
Kidney transplantation has become the best replacement therapy for patients with chronic renal failure, one-year survival rate after transplantation has improved markedly. Graft failure from immunologic factors and death from opportunistic infection in the first year after transplantation are no longer common clinical outcomes other than 30 years ago. However, the long-term outcome of the graft is still poor because of allograft dysfunction after transplantation. Intensity of acute rejection and effect of treatment have direct impact on the long-term outcome of the graft. It is crucial that a definite diagnosis should be as early as possible. How to detect rejection and distinguish it from other causes of renal dysfunctionn is still an challenging topic in the transplantation field.
With the application of new immunosuppressive agents, more and more patients presented with atypical clinical manifestation of acute rejection, Histopathologic examination of renal biopsy is regarded as the gold standard of acute rejection. But biopsy is limited by the invasive nature of the procedure and cost. Morever, because of the inadequate sample size and sampling error, there have been conflicting results of the histological findings. Some patients with stable renal function were detected with abnormal pathological presentation in protocol biopsies. Current Banff criteria is not sufficient for clinical practice in some atypical cases. To target individualized immunosuppressive regemin, it is important to evaluate the immune state of this special population.
In recent years, researchers have been dedicated to explore more sensitive and timely indicators for the diagnosis of early renal allograft dysfunction. Many noninvasive test supplementing the biopsy has been used for monitoring acute rejection. For example, noninvasive tests in kidney transplants by measure of Mig, IP 10, Tim-3, Fractalkine in urine.
The aim of this study is to investigate whether level of sTim-3, Fractalkine and BCA-1 in urine is a useful noninvasive tool for the assessment of acute rejection in renal transplant recipients. Our topic is expected to provide new noninvasive dignostic marks for acute renal rejection and to provide some clinical basis for future research.
Part I Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients by Measurement of urine sTim-3
Objective:
To investigate the relationship between early-stage renal acute rejection and the level of sTim-3 in urine, explore the diagnostic value and noninvasive monitoring in early stage after transplantation by measurement of urine sTim-3.
Methods
We examined urine samples from renal transplant patients between January 2006 and October 2009.155 patients were enrolled, including 49 with biopsy-proved acute rejection,58 patients with stable renal function and no abnormal histological findings, 10 patients with subclinical rejection in protocol biopsy,9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urinary samples were also collected from 40 healthy controls. sTim-3 was measured in urinary samples using a commercial human sTim-3 enzyme-linked immunosorbent assay (ELISA) kit (GBD Systems). All samples were tested in duplicate by a standardized ELISA technique. Statistical analysis was performed by using SPSS software package. (Version 16.0) Because of nonparametric distribution, comparisons of sTim-3 levels among different groups were performed by Kruskal-Wallis test or Mann-Whitney U test and Wilcoxon Signed Ranks Test. A conventional receiver operating characteristic (ROC) curve was applied to determine the sensitivities and specificities for sTim-3 measurements for patients with acute rejection, subclinical rejection and steroid-resistant acute rejection. Area under the curve was also calculated. Results were expressed in the text as mean±SEM unless otherwise stated. P<0.05 was considered statistically significant. sTim-3 levels were expressed per millimole of urinary creatinine to correct for difference in urinary concentration. Immunohistochemistry for Tim-3 expression was performed on biopsies from renal transplant patients with acute rejection and No-AR.
Results
Patient with acute rejection excreted urinary sTim-3 at a significantly higher level (4257±439.4,95%CI:3373-5142 ng/mmol creatine) than levels of patients with No-AR and healthy controls (P<0.001). Patients with acute tubular necrosis excreted urinary sTim-3 at a significantly lower level (2180±217,95%CI:1679-2680 ng/mmol creatine) than levels of patients with acute rejection. ROC curve was constructed to determine the discriminatory power of sTim-3 levels for diagnosis of acute rejection. The area under ROC curve was 0.874 (95%CI:0.8-0.948), which showed that sTim-3 was a suitable marker for the diagnosis of acute rejection. At a cut point of 1836 ng/mmol creatinine, the sensitivity was 89.4% and the specificity was 82.5%(P<0.001). Patients with steroid-resistant acute rejection had significantly greater urinary sTim-3 concentration than patients with steroid-sensitive acute rejection (5548±613.5,95%CI: 4287-6809 ng/mmol creatinine vs 2653±391.7,95%CI:1830-3476 ng/mmol creatinine, P=0.0002).The dynamic level of urinary sTim-3 in acute renal rejection patients within 3 weeks after transplantation is about 6000 ng/mmol creatine, which is remarkably higher than patients with stable renal function (2000 ng/mmol creatinine). We also find that sporadic expression of Tim-3 was present on biopsies from patients with acute rejection and none in patients with No-AR.
Conclusions
The monitoring of sTim-3 in urine may be a new and noninvasive approach for detection acute rejection as well as useful to predict response to antirejection therapy. It has good sensitivity and specificity. Besides, measurement of sTim-3 in urine is a simple, inexpensive method for the routine clinical monitoring after kidney transplantation.
PartⅡNoninvasive Diagnostic and Predictive Value in Renal Transplant Recipients by Measurement of urine Fractalkine
Objective
To investigate the relationship between early-stage renal acute rejection and the level of Fractalkine in urine, explore the diagnostic value and noninvasive monitoring in early stage after transplantation by measurement of urine Fractalkine.
Methods
We examined urine samples from renal transplant patients between January 2006 and October 2009.155 patients were enrolled, including 49 with biopsy-proved acute rejection,58 patients with stable renal function and no abnormal histological findings, 10 patients with subclinical rejection in protocol biopsy,9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urinary samples were also collected from 40 healthy controls. Fractalkine was measured in urinary samples using a commercial human Fractalkine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems). All samples were tested in duplicate by a standardized ELISA technique. Statistical analysis was performed by using SPSS software package. (Version 16.0) Because of nonparametric distribution, comparisons of Fractalkine levels among different groups were performed by Kruskal-Wallis test or Mann-Whitney U test and Wilcoxon Signed Ranks Test. A conventional receiver operating characteristic (ROC) curve was applied to determine the sensitivities and specificities for Fractalkine measurements for patients with acute rejection, subclinical rejection and steroid-resistant acute rejection. Area under the curve was also calculated. Results were expressed in the text as mean±SEM unless otherwise stated. P<0.05 was considered statistically significant. Fractalkine levels were expressed per millimole of urinary creatinine to correct for difference in urinary concentration. Immunohistochemistry for Fractalkine expression was performed on biopsies from renal transplant patients with acute rejection and No-AR.
Results
Patient with acute rejection excreted urinary Fractalkine at a significantly higher level (429.1±56.1,95%CI:316.2-541.9 ng/mmol creatine) than levels of patients with No-AR and healthy controls (P<0.001). Patients with acute tubular necrosis excreted urinary Fractalkine at a significantly lower level (133±9.8,95%CI:110.3-155.7 ng/mmol creatine) than levels of patients with acute rejection. ROC curve was constructed to determine the discriminatory power of Fractalkine levels for diagnosis of acute rejection. The area under ROC curve was 0.909 (95%CI:0.856-0.962), which showed that Fractalkine was a suitable marker for the diagnosis of acute rejection. At a cut point of 144.6 ng/mmol creatinine, the sensitivity was84% and the specificity was 81%(P<0.001). Patients with steroid-resistant acute rejection had significantly greater urinary Fractalkine concentration than patients with steroid-sensitive acute rejection (526.8±85.5,95%CI:351-702.5 ng/mmol creatinine vs 309.6±81.6,95%CI: 135.7-483.4 ng/mmol creatinine, P=0.01).The dynamic level of urinary Fractalkine in acute renal rejection patients within 3 weeks after transplantation fluctuated during 400-600 ng/mmol creatine, which is remarkably higher than patients with stable renal function (100-150 ng/mmol creatinine). We also find that widespread expression of Fractalkine was present on biopsies from almost patients with acute rejection and few patients with No-AR.
Conclusions
As a noninvasive monitoring, Fractalkine in urine may be a new approach for detection acute rejection as well as useful to predict response to antirejection therapy. It has good sensitivity and specificity. Besides, measurement of Fractalkine in urine is a simple, inexpensive method for the routine clinical monitoring after kidney transplantation.
Part III Noninvasive Diagnostic and Predictive Value in Renal Transplant Recipients by Measurement of urine BCA-1
Objective
To investigate the relationship between early-stage renal acute rejection and the level of BCA-1 in urine, explore the diagnostic value and noninvasive monitoring in early stage after transplantation by measurement of urine BCA-1.
Methods
We examined urine samples from renal transplant patients between January 2006 and October 2009.155 patients were enrolled, including 49 with biopsy-proved acute rejection,58 patients with stable renal function and no abnormal histological findings,9 patients with biopsy-proven acute tubular necrosis and 29 patients with biopsy-proven chronic allograft nephropathy. Additionally, urinary samples were also collected from 40 healthy controls. BCA-1 was measured in urinary samples using a commercial human BCA-1 enzyme-linked immunosorbent assay (ELISA) kit ((R&D Systems). All samples were tested in duplicate by a standardized ELISA technique. Statistical analysis was performed by using SPSS software package. (Version 16.0) Because of nonparametric distribution, comparisons of BCA-1 levels among different groups were performed by Kruskal-Wallis test or Mann-Whitney U test and Wilcoxon Signed Ranks Test. A conventional receiver operating characteristic (ROC) curve was applied to determine the sensitivities and specificities for BCA-1 measurements for patients with acute rejection, acute humoral rejection and steroid-resistant acute rejection. Area under the curve was also calculated. Results were expressed in the text as mean±SEM unless otherwise stated. P<0.05 was considered statistically significant. BCA-1 levels were expressed per micromole of urinary creatinine to correct for difference in urinary concentration.
Results
Patient with acute rejection excreted urinary BCA-1 at a significantly higher level (8.1±2.1,95%CI:3.9-12.4 pg/μmol creatine) than levels of patients with No-AR and healthy controls (P<0.001). Patients with acute tubular necrosis excreted urinary BCA-1 at a significantly lower level (2.52±0.57,95%CI:1.21-3.84pg/μmol creatinine) than levels of patients with acute rejection. ROC curve was constructed to determine the discriminatory power of BCA-1 levels for diagnosis of acute rejection. The area under ROC curve was 0.881 (95%CI:0.811-0.951), which showed that BCA-1 was a suitable marker for the diagnosis of acute rejection. At a cut point of 0.23 pg/μmol creatine, the sensitivity was 81.6% and the specificity was 87.9%(P<0.001). Patients with steroid-resistant acute rejection had significantly greater urinary BCA-1 concentration than patients with steroid-sensitive acute rejection (11±2.82,95%CI:5.22-16.8 pg/μmol creatinine vs 5.34±4.28,95%CI:3.8-14.5 pg/μmol creatinine, P=0.0032). Patients with acute humoral rejection had significantly higher urinary BCA-1 concentration than patients with acute celluar rejection (24.2±6.68,95%CI:9.5-38.9 pg/μmol creatinine vs 2.91±0.65,95%CI:1.6-4.22 pg/μmol creatinine, P=0.0002). ROC curve was constructed to determine the discriminatory power of BCA-1 levels for diagnosis of acute humoral rejection. The area under ROC curve was 0.867 (95%CI:0.725-1.005), which showed that BCA-1 was a suitable marker for the diagnosis of acute humoral rejection. At a cut point of 8.3 pg/μmol creatine, the sensitivity was 75% and the specificity was 91.9% The dynamic level of urinary BCA-1 in acute renal rejection patients within 3 weeks after transplantation is above 2 pg/μmol creatine, however, the level of patients with stable renal function is below 2 pg/μmol creatine.
Conclusions
The monitoring of BCA-1 in urine may be a new and noninvasive approach for detection acute rejection as well as useful to discriminate the type of rejection. It has good sensitivity and specificity.
引文
[1]Thongboonkerd V, Mcleish KR, Arthur JM, et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002,62:1461-9.
[2]Pieper R, Gatlin CL, Mcgrath AM, et al. Characterization of the human urinary proteome:a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004; 4:1159-74.
[3]Oriordan E, Orlova TN, Mei JF, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004; 15:3240-8.
[4]Voshol H, Brendlen N, Muller D, et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. Proteomics 2005; 4:1192-9.
[5]Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344:947-54.
[6]Hancock WW, Wang L, Ye Q, et al.. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15:479-86.
[7]Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4:432-7.
[8]Peng W, Chen J, Jiang Y, et al..Urinary fractalkine is a marker of acute rejection. Kidney Int.2008 Dec;74(11):1454-60.
[9]Teppo AM, Willebrand EV, Honkanen E, et al. Soluble intercellular adhesion
molecule-1 (sICAM-1) after kidney transplantation:the origin and role of urinary sICAM-1? Transplantation 2001; 71:1113-9.
[10]Lederer SR, Friedrich N, Regenbogen C, et al. Non-invasive monitoring of renal transplant recipients:urinary excretion of soluble adhesion molecules and of the complement-split product C4d. Nephron Clin Pract 2003; 94:19-26.
[11]Renesto PG, Ponciano VC, Cenedeze MA, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant,2007,7 (6):1661-5.
[12]Ponciano VC, Renesto PG, Nogueira E, et al. Tim-3 expression in human kidney allografts. Transpl Immunol,2007,17 (3):215-22.
[13]Hsieh HG, Loong CC, Lui WY, et al. IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection. Transpl Int 2001; 14:287-98
[14]Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197:322-32.
[15]Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-23.
[16]Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report:new diagnostic insights and standards. Am J Transplant 2004; 4:1562-6
[17]Wu JY, Chen JH, Wang YM, et al. Improved clinical outcomes in Chinese renal allograft recipients receiving lower dose immunosuppressants. Transplantation, 2004,78:713-718.
[18]Meier-kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-83.
[19]Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal albograft rejection in cycbosporine-treated recipients. Transplantation,1996, 62:1235-1241.
[20]Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-23.
[21]McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol, 2001,2(12):1109-16.
[22]Frisancho-Kiss S, Nyland JF, Davis SE, et al. Cutting edge:T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol,2006,176 (11):6411-5.
[23]Khademi M, Illes Z, Gielen AW, et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Thl and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol,2004,172 (11):7169-76.
[24]Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance. Nat Immunol,2003,4 (11):1093-101.
[25]Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol,2005,6 (12):1245-52.
[26]Wang F, He W, Zhou H, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol,2008,1-2:68-74.
[27]Zheng XX, Sanchez-Fueyo, Domenig C, et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev,2003,196:75-84.
[28]Jiang S, Lechler RI. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant,2003,3:516-524.
[29]Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States,1988 to 1996. N Engl J Med,2000,342: 605-612.
[30]Wevwer PC, Aten J, Rentenaar RJ, et al. Apoptotic tubular cell death during acute renal allograft rejection. Clin Nephrol,1998,49:28-34.
[31]Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol,2003,4 (11):1102-10.
[32]Monney L, Sabatos CA, Gaglia JL, et al. Thl-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 2002,415 (6871):536-41.
[33]Muthukumarana PA, Zheng XX, Rosengard BR, et al. In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFbeta, but has no immediate effect on Foxp3. Transpl Int.2008 Jun;21(6):593-7.
[34]Ponciano VC, Renesto PG, Nogueira E, et al. Tim-3 expression in human kidney allografts. Transpl Immunol,2007,17 (3):215-22.
[35]Hancock WW, Wang L, Ye Q, et al.. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15:479-86
[36]Peng W, Chen J, Jiang Y, et al..Urinary fractalkine is a marker of acute rejection. Kidney Int.2008 Dec;74(11):1454-60.
[37]Almond P, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal albograft recipients. Transplantation,1993,55:752-757.
[38]Tesi R, Henry M, Elkhammas E, et al. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant,1996,7:345-352.
[39]Massy Z, Guijarro C, Wiederkehr M, et al. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int,1996,49:518-524.
[40]Siddiqi N, McBride MA, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and long-term graft failure:UNOS/OPTN database analysis. Kidney
Int,2004,65:1906-191
[41]Sarwal MM, Jani A, Chang S, et al. Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. Hum Immunol 2001; 62:21-31
[42]Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91:521-30.
[43]Foussat A, Coulomb HA, Gosling J, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000; 30:87-97.
[44]Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domine of fractalkine in cell capture. J Biol Chem 2000; 275:34183-9.
[45]Chen YM, Hu-Tsai MI, Lin SL, et al. Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-Thyl glomerulonephritis in rats. Nephrol Dial Transplant 2003; 18:2505-14.
[46]Chakravorty SJ, Cockwell P, Girdlestone J, et al.. Fractalkine expression on human renal tubular epithelial cells:potential role in mononuclear cell adhesion. Clin Exp Immunol 2002; 129:150-9.
[47]Steinmetz OM, Panzer U, Kneissler U, et al. BCA-1/CXCL13 expression is associated with CXCR5-positive B-cell cluster formation in acute renal transplant rejection.Kidney Int.2005 Apr;67(4):1616-21.
[48]Hayry P. Pathology makes a difference. Transplantation,2000,69:1038-1040.
[49]Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation,1984,32:535-539.
[50]Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection:Reproducibility, sensitivity and clinical correlation. J Am Soc Nephrol,1997,8:1930-1941.
[51]Burdick JF, Berschorner WE, Smith WJ, et al. Characteristics of early routine renal allograft biopsies. Transplantation,1984,38:679-684.
[52]Kummer JA, Wever PC, Kamp AM, et al. Expression of granzyme A and B proteins by cytotoxic lymphocytes involved in acute renal allograft rejection. Kidney Int,1995,47:70-77.
[53]Legler DF, Loetscher M, Roos RS, et al. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med.1998 Feb 16;187(4):655-60.
[54]Gunn MD, Ngo VN, Ansel KM, et al. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature.1998 Feb 19;391(6669):799-803.
[55]Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol.1997 Jul;151(1):97-110.
[56]Velaga S, Herbrand H, Friedrichsen M, et al.Chemokine receptor CXCR5 supports solitary intestinal lymphoid tissue formation, B cell homing, and induction of intestinal IgA responses. J Immunol.2009 Mar 1;182(5):2610-9.
[57]Mueller SN, Hosiawa-Meagher KA, Konieczny BT, et al. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science.2007 Aug 3;317(5838):670-4.
[58]Dobner T, Wolf I, Emrich T, et al.Differentiation-specific expression of a novel G protein-coupled receptor from Burkitt's lymphoma. Eur J Immunol.1992 Nov;22(11):2795-9.
[59]Kaiser E, Forster R, Wolf I, et al.The G protein-coupled receptor BLR1 is involved in murine B cell differentiation and is also expressed in neuronal tissues. Eur J Immunol.1993 Oct;23(10):2532-9.
[60]Forster R, Emrich T, Kremmer E, et al.Expression of the G-protein--coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood.1994 Aug 1;84(3):830-40.
[61]Forster R, Mattis AE, Kremmer E, et al.A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell.1996 Dec 13;87(6):1037-47.
[62]Smith JR, Braziel RM, Paoletti S, et al.Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood.2003 Feb 1;101(3):815-21. Epub 2002 Oct 3.
[63]Amft N, Curnow SJ, Scheel-Toellner D, et al Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum.2001 Nov;44(11):2633-41.
[64]Shi K, Hayashida K, Kaneko M, et al Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol.2001 Jan 1;166(1):650-5.
[65]MAZZUCCHELLI L, BLASER A, KAPPELER A, et al:BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lym-phoid tissue and gastric lymphoma. J Clin Invest.1999,104:R49-54.
[66]ISHIKAWA S, SATO T, ABE M, et al:Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+den-dritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 2001,193:1393-1402.
[67]Janeway CA. Immunobiology:the Immune System in Health and Disease,4th ed. NewYork:Current Biology Publications,1999.307-361.
[68]SARWAL M, CHUA MS, KAMBHAM N, et al:Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349:125-138,2003.
[69]Steinmetz OM, Stahl RA, Panzer U.Chemokines and B cells in renal inflammation and allograft rejection. Front Biosci (Schol Ed).2009 Jun 1;1:13-22.
[70]Jenh CH, Cox MA, Hipkin W, et al Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine.2001 Aug 7;15(3):113-21.
[71]Ansel KM, Harris RB, Cyster JG.CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity.2002 Jan;16(1):67-76.
[72]袁劲,TIM-3-TIM-3L通路在天然调节性T细胞和诱导调节性T细胞免疫抑制效应中的研究[博士学位论文]湖北武汉华中科技大学2007,58-72.
[1]McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol, 2001,2(12):1109-16.
[2]Frisancho-Kiss S, Nyland JF, Davis SE, et al. Cutting edge:T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol,2006,176 (11):6411-5.
[3]Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1):a novel biomarker for human renal proximal tubule injury. Kidney Int,2002,62 (1): 237-44.
[4]Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem,1998,273 (7): 4135-42.
[5]Kuchroo VK, Umetsu DT, DeKruyff RH, et al. The TIM gene family:emerging roles in immunity and disease. Nat Rev Immunol,2003,3 (6):454-62.
[6]Khademi M, Illes Z, Gielen AW, et al. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol,2004,172 (11):7169-76.
[7]Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto-and alloimmune responses and promotes immunological tolerance. Nat Immunol,2003,4 (11):1093-101.
[8]Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol,2005,6 (12):1245-52.
[9]Wang F, He W, Zhou H, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol,2008,1-2:68-74.
[10]Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol,2003,4 (11):1093-101.
[11]Sui L, Zhang W, Chen Y, et al. Human membrane protein Tim-3 facilitates hepatitis A virus entry into target cells. Int J Mol Med,2006,17 (6):1093-9.
[12]Mariat C, Sanchez-Fueyo A, Alexopoulos SP, et al. Regulation of T cell dependent immune responses by TIM family members. Philos Trans R Soc Lond B Biol Sci, 2005,360(1461):1681-5.
[13]Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 2002,415 (6871):536-41.
[14]Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol,2003,4 (11):1102-10.
[15]Wang H, DeVries ME, Deng S, et al. The axis of interleukin 12 and gamma interferon regulates acute vascular xenogeneic rejection. Nat Med,2000,6 (5): 549-55.
[16]Sharma VK, Bologa RM, Xu GP, et al. Intragraft TGF-beta 1 mRNA:a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int,1996,49 (5): 1297-303.
[17]Renesto PG, Ponciano VC, Cenedeze MA, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant,2007,7 (6):1661-5.
[18]Ponciano VC, Renesto PG, Nogueira E, et al. Tim-3 expression in human kidney allografts. Transpl Immunol,2007,17 (3):215-22.
[19]Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol,2005,6 (12):1245-52.
[20]Wang F, He W, Zhou H, et al. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol,2008,1-2:68-74.
[21]Muthukumarana PA, Zheng XX, Rosengard BR, et al. In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFbeta, but has no immediate effect on Foxp3. Transpl Int.2008 Jun;21(6):593-7.
1. Medawar PB. Harvey Lect,1956 (Series 52):144-76.
2. Monaco AP, Clark AW, Wood ML, et al. Surgery,1976,79 (4):384-92.
3. Barber WH, Mankin JA, Laskow DA, et al. Transplantation,1991,51 (1):70-5.
4. Gleit ZL, Fuchimoto Y, Yamada K, et al. Transplantation,2002,74 (11):1535-44.
5. Ciancio G, Miller J, Garcia-Morales RO, et al. Transplantation,2001,71 (7): 827-35.
6. Millan MT, Shizuru JA, Hoffmann P, et al. Transplantation,2002,73 (9):1386-91.
7. De Pauw L, Toungouz M, Goldman M. Transplantation,2003,75 (9 Suppl): 46S-49S.
8. Trivedi HL, Vanikar AV, Vakil JM, et al.Nephrol Dial Transplant,2004,19 (9): 2374-7.
9. Scandling JD, Busque S, Dejbakhsh-Jones S, et al.N Engl J Med,2008,358 (4): 362-8.
10. Starzl TE. N Engl J Med,2008,358 (4):407-11.
11. Demetris AJ, Murase N, Starzl TE.Lancet,1992,339 (8809):1610.
12. Levy AE, Alexander JW, Babcock GF. Transpl Immunol,1997,5 (2):83-8.
13. Starzl TE, Demetris AJ, Murase N, et al. Lancet,1992,339 (8809):1579-82.
14. Ciancio G, Burke GW, Garcia-Morales R, et al. Transplantation,2002,74 (4): 488-96.
15. Ciancio G, Garcia-Morales R, Mathew J, et al. Transplant Proc,2001,33 (1-2): 1295-6.
16.陈江华,王仁定,吴建永,等.中华肾脏病杂志,2003,(6)
17.何强,吴建永,姜睿,等.中华医学杂志,2006,(36).
18. Freeman GJ, Borriello F, Hodes RJ, et al. J Exp Med,1993,178 (6):2185-92.
19. Gur H, Krauthgamer R, Berrebi A, et al. Blood,2002,99 (11):4174-81.
20. McDaniel DO, Naftilan J, Hulvey K, et al. Transplantation,1994,57 (6):852-6.